34 research outputs found
Management of Cerebral Venous Thrombosis Due to Adenoviral COVID-19 Vaccination
Objective Cerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus-based severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance of platelet transfusion. The aim of this study was to evaluate adherence to these recommendations and its association with mortality. Methods We used data from an international prospective registry of patients with CVT after the adenovirus-based SARS-CoV-2 vaccination. We analyzed possible, probable, or definite VITT-CVT cases included until January 18, 2022. Immunomodulation entailed administration of intravenous immunoglobulins and/or plasmapheresis. Results Ninety-nine patients with VITT-CVT from 71 hospitals in 17 countries were analyzed. Five of 38 (13%), 11 of 24 (46%), and 28 of 37 (76%) of the patients diagnosed in March, April, and from May onward, respectively, were treated in-line with VITT recommendations (p < 0.001). Overall, treatment according to recommendations had no statistically significant influence on mortality (14/44 [32%] vs 29/55 [52%], adjusted odds ratio [OR] = 0.43, 95% confidence interval [CI] = 0.16-1.19). However, patients who received immunomodulation had lower mortality (19/65 [29%] vs 24/34 [70%], adjusted OR = 0.19, 95% CI = 0.06-0.58). Treatment with non-heparin anticoagulants instead of heparins was not associated with lower mortality (17/51 [33%] vs 13/35 [37%], adjusted OR = 0.70, 95% CI = 0.24-2.04). Mortality was also not significantly influenced by platelet transfusion (17/27 [63%] vs 26/72 [36%], adjusted OR = 2.19, 95% CI = 0.74-6.54). Conclusions In patients with VITT-CVT, adherence to VITT treatment recommendations improved over time. Immunomodulation seems crucial for reducing mortality of VITT-CVT. ANN NEUROL 2022Peer reviewe
Sex differences in cerebral venous sinus thrombosis after adenoviral vaccination against COVID-19
Introduction: Cerebral venous sinus thrombosis associated with vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) is a severe disease with high mortality. There are few data on sex differences in CVST-VITT. The aim of our study was to investigate the differences in presentation, treatment, clinical course, complications, and outcome of CVST-VITT between women and men. Patients and methods: We used data from an ongoing international registry on CVST-VITT. VITT was diagnosed according to the Pavord criteria. We compared the characteristics of CVST-VITT in women and men. Results: Of 133 patients with possible, probable, or definite CVST-VITT, 102 (77%) were women. Women were slightly younger [median age 42 (IQR 28â54) vs 45 (28â56)], presented more often with coma (26% vs 10%) and had a lower platelet count at presentation [median (IQR) 50x109/L (28â79) vs 68 (30â125)] than men. The nadir platelet count was lower in women [median (IQR) 34 (19â62) vs 53 (20â92)]. More women received endovascular treatment than men (15% vs 6%). Rates of treatment with intravenous immunoglobulins were similar (63% vs 66%), as were new venous thromboembolic events (14% vs 14%) and major bleeding complications (30% vs 20%). Rates of good functional outcome (modified Rankin Scale 0-2, 42% vs 45%) and in-hospital death (39% vs 41%) did not differ. Discussion and conclusions: Three quarters of CVST-VITT patients in this study were women. Women were more severely affected at presentation, but clinical course and outcome did not differ between women and men. VITT-specific treatments were overall similar, but more women received endovascular treatment.</p
Sex differences in cerebral venous sinus thrombosis after adenoviral vaccination against COVID-19
Introduction: Cerebral venous sinus thrombosis associated with vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) is a severe disease with high mortality. There are few data on sex differences in CVST-VITT. The aim of our study was to investigate the differences in presentation, treatment, clinical course, complications, and outcome of CVST-VITT between women and men. Patients and methods: We used data from an ongoing international registry on CVST-VITT. VITT was diagnosed according to the Pavord criteria. We compared the characteristics of CVST-VITT in women and men. Results: Of 133 patients with possible, probable, or definite CVST-VITT, 102 (77%) were women. Women were slightly younger [median age 42 (IQR 28â54) vs 45 (28â56)], presented more often with coma (26% vs 10%) and had a lower platelet count at presentation [median (IQR) 50x109/L (28â79) vs 68 (30â125)] than men. The nadir platelet count was lower in women [median (IQR) 34 (19â62) vs 53 (20â92)]. More women received endovascular treatment than men (15% vs 6%). Rates of treatment with intravenous immunoglobulins were similar (63% vs 66%), as were new venous thromboembolic events (14% vs 14%) and major bleeding complications (30% vs 20%). Rates of good functional outcome (modified Rankin Scale 0-2, 42% vs 45%) and in-hospital death (39% vs 41%) did not differ. Discussion and conclusions: Three quarters of CVST-VITT patients in this study were women. Women were more severely affected at presentation, but clinical course and outcome did not differ between women and men. VITT-specific treatments were overall similar, but more women received endovascular treatment.</p
Multiple Sclerosis, Spasticity and Nabiximols: A User Experience
This clinical case concerns a 54-year-old woman with onset of multiple sclerosis at the age of 21 years, a long remission for 12 years and a subsequent resumption of disease activity partially contained by therapies. Not surprisingly, the increased burden of disability and impairment of quality of life is related not so much to the severity of the neurological damage as to the spasticity associated with the disease, which is responsible for severe alterations to posture control and trunk instability. A complex therapeutic strategy pathway started combining physical and pharmacological treatment, which reached a delicate balance with the introduction of nabiximols
Recommended from our members
Hairdresserâs Dystonia: An Unusual Occupational Dystonia
Adult-onset focal dystonias (AOFDs) are non-task-specific or task-specific and may spread to other body segments of affected patients. Case report We report the case of a barber with non-task-specific craniocervical dystonia and a new occupational focal hand dystonia (while using scissors). Discussion Different AOFDs may develop and coexist in the same "vulnerable" patient. Hairdresserâs dystonia is a rare task-specific dystonia
Recommended from our members
Hairdresser's Dystonia: An Unusual Occupational Dystonia
Background: Adultâonset focal dystonias (AOFDs) are nonâtaskâspecific or taskâspecific and may spread to other body segments of affected patients.Case report: We report the case of a barber with nonâtaskâspecific craniocervical dystonia and a new occupational focal hand dystonia (while using scissors). Discussion: Different AOFDs may develop and coexist in the same “vulnerable” patient. Hairdresser’s dystonia is a rare taskâspecific dystonia.</p
Recommended from our members
The Progression of Posterior Cortical Atrophy to Corticobasal Syndrome: Lumping or Splitting Neurodegenerative Diseases?
Background: Posterior cortical atrophy is a clinical syndrome that is characterized by the progressive loss of visuospatial integration and is associated with neurodegenerative conditions.Case Report: We describe a 60âyearâold female with simultanagnosia, oculomotor apraxia, and optic ataxia for which she received an initial clinical diagnosis of posterior cortical atrophy. Three years later, she developed Balint's syndrome, Gerstmann's syndrome, left alien hand syndrome, smooth asymmetric (left) rigidity, cortical sensory loss, and spontaneous myoclonic jerks of the left arm, which suggested a final diagnosis of corticobasal syndrome.Discussion: This case report indicates that corticobasal syndrome may present with visuospatial deficits.</p
Recommended from our members
Change in Non-Motor Symptoms in Parkinson's Disease and Essential Tremor Patients: A One-year Follow-up Study
<p><strong>Background: </strong>Nonâmotor symptoms (NMS) in Parkinson's disease (PD) differ from those in essential tremor (ET), even before a definitive diagnosis is made. It is not clear whether patient's knowledge of the diagnosis and treatment influence their subsequent reporting of NMS.</p><p><strong>Methods: </strong>1 year after a clinical and instrumental diagnosis, we compared the motor impairment (Movement Disorders Society (MDS)âUnified Parkinson's Disease Rating ScaleâIII) and nonâmotor symptoms (NMSQuest) in PD (nâ=â31) and ET (nâ=â21) patients.</p><p><strong>Results: </strong>PD patients reported more NMS than did the ET patients (pâ=â0.002). When compared to their baseline report, at followâup, PD patients reported less nocturia (pâ=â0.02), sadness (pâ=â0.01), insomnia (pâ=â0.02), and restless legs (pâ=â0.04) and more nausea (pâ=â0.024), unexplained pain (pâ=â0.03), weight change (pâ=â0.009), and daytime sleepiness (pâ=â0.03). When compared to their baseline report, ET patients reported less loss of interest (pâ=â0.03), anxiety (pâ=â0.006), and insomnia (pâ=â0.02). Differences in reported weight change (p<0.0001) and anxiety (pâ=â0.001) between PD and ET patients were related to pharmacological side effects or to a reduction in the ET individuals.</p><p><strong> </strong></p><p><strong>Discussion: </strong>The reporting of NMS is influenced by subjective factors, and might vary with the patient's knowledge of the diagnosis or the effectiveness of treatment.</p